Published in: Publicaciones

Resumen de las Actividades Nacionales en la Prueba de Enfermedad Renal Crónica (ERC)

Author admin

Published on: octubre 22, 2024

A Summary of Worldwide National Activities in Chronic Kidney Disease (CKD) Testing.

Roberto Ruiz-Arenas¹, Rosa Sierra-Amor¹, David Seccombe², Stella Raymondo³, Maria Stella Graziani⁴, Mauro Panteghini⁴, Tewogbade A Adedeji⁵, Shanthi Naidu Kamatham⁶, Vanja Radišić Biljak⁷Affiliations ExpandPMID: 29333149 PMCID: PMC5746839.

Resumen

La enfermedad renal crónica (ERC) es un importante problema de salud pública en todo el mundo y está asociada con resultados adversos para la salud, especialmente en países de ingresos bajos y medios. En un sistema de salud con recursos limitados, las pautas que mejoran la eficiencia del cuidado de la salud liberan recursos necesarios para otros servicios de atención médica. Esta breve revisión presenta algunos ejemplos de actividades nacionales en la evaluación de la ERC, incluyendo países de todo el mundo: México en América del Norte, Uruguay en América del Sur, Italia en Europa, Nigeria en África e India en Asia. Considerando que el tratamiento de la ERC es rentable y mejora los resultados, esta observación argumenta a favor de incluir la ERC en las pautas nacionales y en los programas de enfermedades crónicas no transmisibles (ECNT). Este diverso ejemplo de actividades nacionales cumple el primer paso para lograr este objetivo.

Abstract

Chronic kidney disease (CKD) is a major public health issue worldwide and is associated with adverse health outcomes, especially in low- and middle-income countries. In a cash-limited healthcare system, guidelines that improve the efficiency of healthcare free up resources needed for other healthcare services. This short review presents some examples from national activities in CKD testing, including countries throughout the globe: Mexico in North America, Uruguay in South America, Italy in Europe, Nigeria in Africa, and India in Asia. Considering the fact that treatment of CKD is cost-effective and improves outcomes, this observation argues in favor of including CKD in national guidelines and noncommunicable chronic disease (NCD) programs. This diverse example of national activities fulfills the very first step in achieving this goal.

References

1. Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, et al. Effective CKD care in European countries: challenges and opportunities for health policy. Am J Kidney Dis 2015;65(1):15-25 – PubMed
2. Radhakrishnan J, Remuzzi G, Saran R, Williams DE, Rios-Burrows N, Powe N, et al. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int 2014;86(2):246-250 – PMC – PubMed
3. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011;80(12):1258-1270 – PubMed
4. Black C, van der Veer SN. Unlocking the Value of Variation in CKD Prevalence. J Am Soc Nephrol 2016;27(7):1874-1877 – PMC – PubMed
5. Tonelli M, Agarwal S, Cass A, Garcia Garcia G, Jha V, Naicker S, Wang H, Yang CW, O’Donoghue D. How to advocate for the inclusion of chronic kidney disease in a national noncommunicable chronic disease program. Kidney Int 2014;85(6):1269-1274 – PubMed
6. Radišić Biljak V, Moberg Aakre K, Yucel D, Bargnoux A-S, Cristol J-P, Piéroni L. A pathway to national guidelines for laboratory diagnostics of chronic kidney disease – examples from diverse European countries. eJIFCC, in press – PMC – PubMed
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150
8. Al Shamsi S, Al Dhanhani A, Sheek-Hussein MM, Bakoush O. Provision of care for chronic kidney disease by non-nephrologists in a developing nation: a national survey. BMJ Open 2016;6(8): e010832 – PMC – PubMed
9. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999;318:527-530 – PMC – PubMed
10. Da Silvera-Martínez R, Jiménez-Gutiérrez R. Optimización de la creatinina al estimar la tasa de filtración glomerular en el laboratorio. Rev Med Inst Mex Seguro Soc 2011;49(5):481-486 – PubMed
11. http://www.usrds.org. Accessed 20th July 2017.
12. Komenda P, Beaulieu M, Seccombe D, Levin A. Regional implementation of creatinine measurement standardization. J Am Soc Nephrol. 2008;19:164-169 – PMC – PubMed
13. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006;52(1):5-18 – PubMed
14. Zoccali C, Cappelletti P, Plebani M. Valutazione di laboratorio della funzionalità renale. Biochim Clin 2009;33:144-145
15. Istituto Superiore di Sanità. Sistema nazionale per le Linee Guida. Linea Guida 23. Identificazione, prevenzione e gestione della malattia renale cronica nell’adulto. www.snIg-iss.it
16. Carobene A, Ceriotti F, Infusino I, Frusciante E, Panteghini M. Evaluation of the impact of standardization process on the quality of serum creatinine determination in Italian laboratories. Clin Clin Acta 2014;427:100-106 – PubMed
17. Graziani MS, Secchiero S, Terreni A, Caldini A, Panteghini M. La diagnostica di laboratorio della malattia renale cronica in Italia: armonizzare è d’obbligo. Biochim Clin 2015;39:617-626
18. Panteghini M. Enzymatic assays for creatinine: time for action. Biochim Clin 2008;32:203-208 – PubMed
19. Ceriotti F. Determinazione della creatinina: per i laboratori è tempo di agire. Biochim Clin 2010;34:9-10
20. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, Patel U. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(3)- PubMed
21. Afolabi MO, Abioye-Kuteyi EA, Arogundade FA, Bello IS. Prevalence of CKD in a Nigerian family practice population. SA Fam Pract 2009;51:131-137
22. Adebisi SA. Routine reporting of estimated glomerular filtration rate (eGFR) in African Laboratories and the need for its increased utilisation in Clinical Practice. The Nigerian Postgraduate Medical Journal. 2013;20(1):57-62 – PubMed
23. Enem CP, Arogundade F, Sanusi A, et al. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant. 2008;23(2):741–746 – PubMed
24. Adedeji TA, Adebisi SA, Akande AA, Adedeji NO, Ajose AO, Idowu AA, Fawale MB, Olanrewaju TO, Okunola O, Akinsola A. Sustained Improvement in Glomerular Filtration Rate after Four Weeks on Highly Active Antiretroviral Therapy. Journal of Therapy and Management in HIV Infection. 2014;2:50-57
25. Adedeji TA, Adedeji NO, Adebisi SA, Idowu AA, Fawale MB, Jimoh KA. Prevalence and Pattern of Chronic Kidney Disease in Antiretroviral-Naive Patients with HIV/AIDS. Journal of the International Association of Providers of AIDS Care. 2015;14(5):434-440 – PubMed
26. Ifeoma I. Ulasi and Chinwuba K. Ijoma. The Enormity of Chronic Kidney Disease in Nigeria: The Situation in a Teaching Hospital in South-East Nigeria. J Trop Med 2010; Article ID 501957, 6 pages – PMC – PubMed
27. Sanusi AA, Akinsola A, Ajayi AA. Creatinine clearance estimation from serum creatinine values: evaluation and comparison of five prediction formulae in Nigerian patients. Afr J Med Med Sci 2000;29:7–11 – PubMed
28. Sanusi AA, Arogundade FA, Akintomide AO, Akinsola A. Utility of predicted creatinine clearance using MDRD formula compared with other predictive formulas in Nigerian patients